A new imaging agent appears capable of
distinguishing aggressive from benign prostate cancer, potentially helping doctors select with better precision those patients in need of more extensive treatment, a pre-clinical study finds.
So far only tested in mice, the imaging agent makes use of a newly identified protein only present in aggressive prostate cancer forms. A more precise way of diagnosing this type of prostate cancer would both allow early treatment of those in need, and spare patients with slow-growing tumors unnecessary side effects.
In addition, the imaging method could be used to monitor patients with slow-growing tumors for changes, detecting if a tumor turns aggressive.